Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang

Halozyme Therapeutics (HALO) just added seasoned healthcare dealmaker Jim Lang to its board, and that move has investors asking whether fresh strategic eyes could help unlock more value after a mixed few months for the stock.

See our latest analysis for Halozyme Therapeutics.

The timing is interesting, as Halozyme’s share price sits at 63.45 dollars after a solid year to date share price return of just over 32 percent. However, the 3 year total shareholder return is a more modest 12 percent, suggesting recent momentum has picked up after a softer multi year stretch.

If this kind of board level refresh has you thinking about what else might be setting up for the next leg higher, it could be worth exploring other healthcare stocks that are quietly building momentum too.

With earnings still growing, the share price below analyst targets, and a hefty implied discount to intrinsic value, is Halozyme quietly undervalued here, or is the market already baking in its next leg of growth?

Most Popular Narrative Narrative: 16.5% Undervalued

With Halozyme Therapeutics trading at 63.45 dollars versus a most popular narrative fair value of 76 dollars, the story hinges on sustained earnings power and margins.

The analysts have a consensus price target of $70.556 for Halozyme Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $91.0, and the most bearish reporting a price target of just $51.0.

Read the complete narrative.

Want to see what justifies that higher fair value? The narrative leans on rapid top line expansion, rising profitability, and a surprisingly low future earnings multiple. Curious which levers really move the model?

Result: Fair Value of $76 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent patent litigation and heavy reliance on a few blockbuster partnerships could quickly pressure Halozyme’s royalty growth and challenge that undervaluation story.

Find out about the key risks to this Halozyme Therapeutics narrative.

Build Your Own Halozyme Therapeutics Narrative

If this interpretation does not quite match your view, or you prefer to dig into the numbers yourself, you can build a custom narrative in just a few minutes using Do it your way.

A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Before you move on, seize this moment to uncover fresh, high conviction opportunities with the Simply Wall Street Screener, so your next winning idea does not slip away.

• Capture potential long term bargains by targeting quality companies trading at attractive prices through these 903 undervalued stocks based on cash flows.
• Fuel your portfolio’s growth engine by focusing on innovation leaders shaping tomorrow’s technology landscape using these 26 AI penny stocks.
• Strengthen your income stream with resilient businesses offering reliable payouts via these 13 dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com